Different ability of clenbuterol and salbutamol to block sodium channels predicts their therapeutic use in muscle excitability disorders

Molecular Pharmacology

Volumn 63, Issue 3, 2003, Pages 659-670

  Desaphy, Jean François ^a   Pierno, Sabata ^a   De Luca, Annamaria ^a   Didonna, Paola ^a   Camerino, Diana Conte ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

8 (4 CHLOROPHENYLTHIO) CYCLIC AMP; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLENBUTEROL; HYDROXYL GROUP; ISOPROTEIN; LIDOCAINE ETHOBROMIDE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NADOLOL; OKADAIC ACID; PROPRANOLOL; SALBUTAMOL; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; STAUROSPORINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC STIMULATION; CONTROLLED STUDY; DRUG BINDING; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG USE; GENE MUTATION; GENETIC CODE; GENETIC DISORDER; GENETIC TRANSFECTION; LOCAL ANESTHESIA; MOLECULAR MODEL; MUSCLE ACTION POTENTIAL; MUSCLE DISEASE; MUSCLE EXCITATION; MUSCLE FIBER MEMBRANE CONDUCTANCE; MUSCLE FIBER MEMBRANE POTENTIAL; MYOTONIA; NONHUMAN; PATCH CLAMP; PERIODIC PARALYSIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SARCOLEMMA; SKELETAL MUSCLE; SODIUM CURRENT; SODIUM TRANSPORT; STRUCTURE ACTIVITY RELATION; SYNDROME DELINEATION;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ALBUTEROL; ANIMALS; CLENBUTEROL; HUMANS; MUSCLE FIBERS; MUSCLE, SKELETAL; MUSCULAR DISEASES; RATS; RECEPTORS, ADRENERGIC, BETA-2; SODIUM CHANNELS;

EID: 0037334542     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.3.659     Document Type: Article

References (38)

1. Ban T, Sada S, Takahashi Y, Sada H, and Fugita T (1985) Effects of para-substituted beta-adrenoceptor blocking agents and methyl-substituted phenoxypropanolamine derivatives on maximum upstroke velocity of action potential in guinea pig papillary muscles. Naunyn-Schmiedeberg's Arch Pharmacol 329:77-85.
2. Bean BP, Cohen CJ, and Tsien RW (1983) Lidocaine block of cardiac sodium channels. J Gen Physiol 81:613-642.
3. + channel by protein kinase C. Proc Natl Acad Sci USA 92:12003-12007.
4. Bowman WC and Nott MW (1969) Actions of sympathomimetic amines and their antagonists on skeletal muscle. Pharmacol Rev 21:27-72.
5. Cannon SC (2001) Voltage-gated ion channelopathies of the nervous system. Clin Neurosci Res 1:104-117.
6. + channels: comparison with other β-adrenoceptor antagonists. Br J Pharmacol 130:759-766.
7. 2-adrenoceptor activation. Am J Physiol 263:E50-E56.
8. +-paralysed rat muscle. J Physiol 472:521-536.
9. Courtney KR (1990) Sodium channel blockers: the size/solubility hypothesis revisited. Mol Pharmacol 37:855-859.
10. Desaphy J-F, De Luca A, and Conte Camerino D (1998a) Blockade by cAMP of native sodium channels of rat skeletal muscle fibers. Am J Physiol 275: C1465-C1472.
11. Desaphy J-F, De Luca A, Pierno S, Imbrici P, and Conte Camerino D (1998b) Partial recovery of skeletal muscle sodium channel properties in aged rats chronically treated with growth hormone or the GH-secretagogue hexarelin. J Pharmacol Exp Ther 286:903-912.
12. Desaphy J-F, De Luca A, Tortorella P, De Vito D, George AL Jr, and Conte Camerino D (2001) Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative. Neurology 57:1849-1857.
13. Fischer W, Kittner H, Regenthal R, Malinowska B, and Schlicker E (2001) Anticonvulsant and sodium channel blocking activity of higher doses of clenbuterol. Naunyn-Schmiedeberg's Arch Pharmacol 363:182-192.
14. Frazier DT, Narahashi T, and Yamada M (1970) The site of action and active form of local anesthetics. Experiments with quaternary compounds. J Pharmacol Exp Ther 171:45-51.
15. Hanna MG, Stewart J, Schapira AHV, Wood NW, Morgan-Hughes J, and Murray NMF (1998) Salbutamol treatment in a patient with hyperkalemic periodic paralysis due to a mutation in the skeletal muscle sodium channel gene (SCN4A). J Neurol Neurosurg Psychiatry 65:248-250.
16. Hayes A and Williams DA (1998) Examining potential drug therapies for muscular dystrophy utilizing the dy/dy mouse: I. Clenbuterol. J Neurol Sci 157:122-128.
17. Herrera NM Jr, Zimmerman AN, Dykstra DS, and Thompson LV (2001) Clenbuterol in the prevention of muscle atrophy: a study of hindlimb-unweighted rats. Arch Phys Med Rehabil 82:930-934.
18. Hille B (2001) Ion Channels of Excitable Membranes. Sinauer Associates Inc., Sunderland, Massachusetts.
19. Hinkle RT, Hodge KMB, Cody DB, Sheldon RJ, Kobilka BK, and Isfort RJ (2002) Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the β2-adrenergic receptor. Muscle Nerve 25:729-734.
20. Kissel JT, McDermott MP, Mendell JR, King WM, Pandya S, Griggs RC, Tawil R and the FSH-DY group (2001) Randomized, double-blind, placebo-controlled trial of albuterol in fascioscapulohumeral dystrophy. Neurology 57:1434-1440.
21. Liggett SB, Shah SD, and Cryer PE (1988) Characterization of β-adrenergic receptors of human skeletal muscle obtained by needle biopsy. Am J Physiol 254:E795-E798.
22. Lu T, Lee H-C, Kabat JA, and Shibata EF (1999) Modulation of rat cardiac sodium channel by the stimulatory G protein α subunit. J Physiol 518.2:371-384.
23. Maltin CA, Delday MI, Watson JS, Heys SD, Nevison IM, Ritchie IK, and Gibson PH (1993) Clenbuterol, a β-adrenoreceptor agonist, increases relative muscle strength in orthopedic patients. Clin Sci 84:651-654.
24. Matsuda JJ, Lee H, and Shibata EF (1992) Enhancement of rabbit cardiac sodium channel by β-adrenergic stimulation. Circ Res 70:199-207.
25. Matthews JC and Baker JK (1982) Effect of propranolol and a number of its analogues on sodium channels. Biochem Pharmacol 31:1681-1685.
26. Meola G (2002) Myotonic dystrophies. Curr Opin Neurol 13:519-525.
27. Moxley RT (2000) Channelopathies. Curr Treatment Opt Neurol 2:31-47.
28. + channels modulate binding affinity and stereoselectivity of local anesthetic enantiomers. Mol Pharmacol 56:404-413.
29. + channels by local anesthetics. Science (Wash DC) 265:1724-1728.
30. + channels. Proc Natl Acad Sci USA 93:9270-9275.
31. + channel. J Physiol 537:701-714.
32. Von Deutsch DA, Abukhalaf IK, Wineski LE, Roper RR, Aboul-Enein HY, Paulsen DF, and Potter DE (2002) Distribution and muscle-sparing effects of clenbuterol in hindlimb-suspended rats. Pharmacology 65:38-48.
33. Wang P and Clausen T (1976) Treatment of hyperkalemic periodic paralysis by inhalation of salbutamol. Lancet 1:221.
34. + channel D3-S6 segment modulate both batrachotoxin and local anesthetic affinities. Biophys J 79:1379-1387.
35. Yang YT and McElligott MA (1989) Multiple actions of β-adrenergic agonists on skeletal muscle and adipose tissue. Biochem J 261:1-10.
36. + channel α-subunit. J Biol Chem 276:20-27.
37. + channel a subunit in voltage-dependent gating and drug block. (July 18, 2002) J Biol Chem 10.1074/jbc. M206126200.
38. Zeman RJ, Peng H, Danon MJ, and Etlinger JD (2000) Clenbuterol reduces degeneration of exercised or aged dystrophic (mdx) muscle. Muscle Nerve 23:521-528.